Document:

Conversion Agreement

 Exhibit 4.6 
 This Agreement (the “Agreement”), dated as of February 27, 2007, is by and among Accentia Biopharmaceuticals, Inc., a Florida corporation (the “Company”) and the investors
signatory hereto (each, a “Purchaser” and collectively, the “Purchasers”). 
 WHEREAS, pursuant to
securities purchase agreement dated September 29, 2006 (the “September 2006 Purchase Agreement”) among the Company, the Purchasers and the other investors signatory thereto, the Company issued and sold secured convertible
debentures (the “September Debentures”) with an aggregate principal amount of $25,000,000, in the individual amounts set forth on Schedule A hereto; 
 WHEREAS, pursuant to a securities purchase agreement to be entered into on or about the date hereof (the “February 2007 Purchase
Agreement”), the Company desires to issue and sell up to $25,000,000 in principal amount of debentures and warrants to purchase shares of Common Stock to the purchasers signatory thereto; 
 WHEREAS, the Purchasers signatory hereto desire to convert a portion of their September Debentures in accordance with the terms hereof; 
 NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for good and valuable consideration the receipt and adequacy of
which are hereby acknowledged, the Purchasers and the Company agree as follows: 
 ARTICLE I 
 DEFINITIONS 
 Section 1.1
Definitions. Capitalized terms not defined in this Agreement shall have the meanings ascribed to such terms in the September 2006 Purchase Agreement. 
 ARTICLE II 
 CONVERSION OF DEBENTURES 
 AND OTHER AGREEMENTS 
 Section 2.1 Conversion of Debentures Each
Purchaser hereby agrees, severally and not jointly with the other Purchasers, to convert a portion of the original principal amount of such Purchaser’s September Debenture, in the individual amounts set forth on Schedule 2.1 attached hereto,
over a six month period, commencing on the date hereof and ending on August 31, 2007 (the “Conversion Period”), otherwise in accordance with the terms of the September Debentures. The Conversion Period set forth in this
Section 2.1 shall be extended for the number of calendar days during such period in which (i) trading in the Common Stock is suspended by any Trading Market, or (ii) the Company’s registration statement on Form S-3, no.
333-138366 registering the resale of the shares of Common Stock underlying the September Debentures and Warrants (the 

  

 1 

 
“September Registration Statement”) is not effective or the prospectus included in such registration statement may not be used by the
selling security holders named therein for the resale of the shares of Common Stock underlying the September Debentures and Warrants. By way of an example, if the prospectus included in the September Registration Statement is unavailable for 20 days
prior to August 31, 2007, the Conversion Period would be extended to September 20, 2007. Notwithstanding the foregoing, a Purchaser shall not be required to convert such certain portion of its September Debenture to the extent that
Section 4(c)(ii) of such debenture is violated by the resulting Common Stock issuance of such certain portion. 
 Section 2.2 February 2007 Purchase Agreement. Each Purchaser party hereto that is a party to the February 2007 Purchase Agreement shall be issued a debenture under such agreement with a principal amount equal to such
Purchaser’s Subscription Amount (as defined in the February 2007 Purchase Agreement) multiplied by 1.38, and otherwise in the form of the debenture attached to the February 2007 Purchase Agreement as Exhibit A, notwithstanding any
contrary provision contained in the February 2007 Purchase Agreement. 
 Section 2.3 Effect on September 2006 Purchase Agreement and
February 2007 Purchase Agreement. Except as expressly set forth herein, all of the terms and conditions of the Transaction Documents shall continue in full force and effect after the execution of this Agreement, and shall not be in any
way changed, modified or superseded by the terms set forth herein. This Agreement shall not constitute a novation or satisfaction and accord of any Transaction Document. 
 Section 2.4 Filing of Form 8-K. Within 1 Trading Day of the date hereof, the Company shall issue a Current Report on Form 8-K, reasonably acceptable to each Purchaser disclosing the material terms of the
transactions contemplated hereby, which shall include this Agreement as an attachment thereto. 
 ARTICLE III 
 REPRESENTATIONS AND WARRANTIES 
 Section 3.1 Representations and Warranties of the Company. The Company hereby make the representations and warranties set forth below to the Purchasers that as of the date of its execution of this Agreement: 
 (a) Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the
transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement by the Company and the consummation by it of the transactions contemplated hereby have been
duly authorized by all necessary action on the part of such Company and no further action is required by such Company, its board of directors or its stockholders in connection therewith. This Agreement has been duly executed by the Company and, when
delivered in accordance with the terms hereof will constitute the valid and binding obligation of the Company enforceable against the 

  

 2 

 
Company in accordance with its terms except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and
(iii) insofar as indemnification and contribution provisions may be limited by applicable law. 
 (b) No
Conflicts. The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the
Company’s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under,
result in the creation of any lien upon any of the properties or assets of the Company, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement,
credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material understanding to which the Company is a party or by which any property or asset of the Company is bound or affected, or (iii) conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including federal and state securities laws and
regulations), or by which any property or asset of the Company is bound or affected. 
 Section 3.2 Representations and Warranties of
the Purchasers. The Purchaser hereby makes the representations and warranties set forth below to the Company that as of the date of its execution of this Agreement: 
 (a) Due Authorization. Such Purchaser represents and warrants that (i) the execution and delivery of this Agreement by it and
the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on its behalf and (ii) this Agreement has been duly executed and delivered by such Purchaser and constitutes the valid and binding
obligation of such Purchaser, enforceable against it in accordance with its terms except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law. 
  

 3 

 ARTICLE IV 
 MISCELLANEOUS 
 Section 4.1 Notices. Any and all notices or other communications or
deliveries required or permitted to be provided hereunder shall be made in accordance with the provisions of the September 2006 Purchase Agreement. 
 Section 4.2 Survival. All warranties and representations (as of the date such warranties and representations were made) made herein or in any certificate or other instrument delivered by it or on its behalf under this Agreement
shall be considered to have been relied upon by the parties hereto. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties; provided however that no party may assign this
Agreement or the obligations and rights of such party hereunder without the prior written consent of the other parties hereto. 
 Section 4.3 Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by
each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission, such signature shall create a valid and binding obligation
of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile signature page were an original thereof. 
 Section 4.4 Severability. If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement
shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this
Agreement. 
 Section 4.5 Governing Law. All questions concerning the construction, validity, enforcement and interpretation of
this Agreement shall be determined pursuant to the Governing Law provision of the September 2006 Purchase Agreement. 
 Section 4.6
Entire Agreement. The Agreement, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or
written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules. 
 Section 4.7 Construction. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. The language used in this Agreement will
be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. 
 Section 4.8 Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser hereunder are several and not joint with the obligations of any other Purchasers hereunder, and
no Purchaser shall be responsible in any way for the 

  

 4 

 
performance of the obligations of any other Purchaser hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and
no action taken by any Purchaser pursuant hereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in
concert with respect to such obligations or the transactions contemplated by this Agreement. Each Purchaser shall be entitled to protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not
be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. 
 Section 4.9
Termination. This Agreement may be terminated by any Purchaser, as to such Purchaser’s obligations hereunder, by written notice to the other parties, if the closing of the transactions contemplated by the February 2007 Purchase
Agreement have not been consummated on or before March 1, 2007. 
 *********************** 
  

 5 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective
authorized signatories as of the date first indicated above. 
  

			
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	By:	 	 /s/ Francis E. O’Donnell, Jr.

	Name:	 	Francis E. O’Donnell, Jr., M.D.
	Title:	 	Chief Executive Officer

  

 6 

 [PURCHASER SIGNATURE PAGES TO ABPI 
 DEBENTURE CONVERSION AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this
Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Purchaser:	  	Wolverine Convertible Arbitrage Fund Trading Ltd.
	Signature of Authorized Signatory of Purchaser:	  	Christopher L. Gust
	Name of Authorized Signatory:	  	Christopher L. Gust
	Title of Authorized Signatory:	  	CIO
	Email Address of Purchaser:	  	convrts.general@wolve.com

  

 7 

 [PURCHASER SIGNATURE PAGES TO ABPI 
 DEBENTURE CONVERSION AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this
Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Purchaser:	  	Midsummer Investment Ltd.
	Signature of Authorized Signatory of Purchaser:	  	Michel Amsalem
	Name of Authorized Signatory:	  	Michel Amsalem
	Title of Authorized Signatory:	  	Director
	Email Address of Purchaser:	  	ma@midsummercapital.com

  

 8 

 [PURCHASER SIGNATURE PAGES TO ABPI 
 DEBENTURE CONVERSION AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this
Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Purchaser:	  	Crescent International Ltd.
	Signature of Authorized Signatory of Purchaser:	  	Bachir Taleb-Ibrahimi
	Name of Authorized Signatory:	  	Bachir Taleb-Ibrahimi
	Title of Authorized Signatory:	  	Authorized Signatory
	Email Address of Purchaser:	  	cantara@dmitrust.com

  

 9 

 [PURCHASER SIGNATURE PAGES TO ABPI 
 DEBENTURE CONVERSION AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this
Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Purchaser:	  	Rockmore Investment Master Fund Ltd.
	Signature of Authorized Signatory of Purchaser:	  	Brian Daly
	Name of Authorized Signatory:	  	Brian Daly
	Title of Authorized Signatory:	  	Managing Member of Rockmore Capital, LLC as Managing Member
	Email Address of Purchaser:	  	  

  

 10 

 [PURCHASER SIGNATURE PAGES TO ABPI 
 DEBENTURE CONVERSION AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this
Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Purchaser:	  	Whitebox Convertible Arbitrage Partners, LP
	Signature of Authorized Signatory of Purchaser:	  	Jonathan Wood
	Name of Authorized Signatory:	  	Jonathan Wood
	Title of Authorized Signatory:	  	Director, CFO
	Email Address of Purchaser:	  	rvogel@whiteboxadvisors.com

  

 11 

 [PURCHASER SIGNATURE PAGES TO ABPI 
 DEBENTURE CONVERSION AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this
Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Purchaser:	  	Whitebox Hedged High Yield Partners, LP
	Signature of Authorized Signatory of Purchaser:	  	Jonathan Wood
	Name of Authorized Signatory:	  	Jonathan Wood
	Title of Authorized Signatory:	  	Director, CFO
	Email Address of Purchaser:	  	rvogel@whiteboxadvisors.com

  

 12 

 [PURCHASER SIGNATURE PAGES TO ABPI 
 DEBENTURE CONVERSION AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this
Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Purchaser:	  	Guggenheim Portfolio Company XXXI LLC
	Signature of Authorized Signatory of Purchaser:	  	Jonathan Wood
	Name of Authorized Signatory:	  	Jonathan Wood
	Title of Authorized Signatory:	  	Director, CFO
	Email Address of Purchaser:	  	rvogel@whiteboxadvisors.com

  

 13 

 [PURCHASER SIGNATURE PAGES TO ABPI 
 DEBENTURE CONVERSION AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this
Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Purchaser:	  	GPC LIX LLC
	Signature of Authorized Signatory of Purchaser:	  	Jonathan Wood
	Name of Authorized Signatory:	  	Jonathan Wood
	Title of Authorized Signatory:	  	Director, CFO
	Email Address of Purchaser:	  	rvogel@whiteboxadvisors.com

  

 14 

 [PURCHASER SIGNATURE PAGES TO ABPI 
 DEBENTURE CONVERSION AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this
Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Purchaser:	  	Pandora Select Partners, LP
	Signature of Authorized Signatory of Purchaser:	  	Jonathan Wood
	Name of Authorized Signatory:	  	Jonathan Wood
	Title of Authorized Signatory:	  	Director, CFO
	Email Address of Purchaser:	  	rvogel@whiteboxadvisors.com

  

 15 

 [PURCHASER SIGNATURE PAGES TO ABPI 
 DEBENTURE CONVERSION AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this
Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Purchaser:	  	Whitebox Intermarket Partners, LP
	Signature of Authorized Signatory of Purchaser:	  	Jonathan Wood
	Name of Authorized Signatory:	  	Jonathan Wood
	Title of Authorized Signatory:	  	Director, CFO
	Email Address of Purchaser:	  	rvogel@whiteboxadvisors.com

  

 16 

 SCHEDULE 2.1 
 DEBENTURE CONVERSION AMOUNTS 
  

							
	 Name of Purchaser
	  	Original
Principal Amount	  	 Amount to be converted
 pursuant to this Agreement

	 Midsummer Investment, Ltd.
	  	$	8,000,000	  	$	4,700,000
			
	 Whitebox Convertible Arbitrage Partners, L.P.
	  	$	3,000,000	  	$	2,437,681
			
	 Whitebox Hedged High Yield Partners, L.P.
	  	$	3,000,000	  	$	2,437,681
			
	 Guggenheim Portfolio Company XXXI LLC
	  	$	300,000	  	$	242,754
			
	 GPC LIX LLC
	  	$	500,000	  	$	406,522
			
	 Pandora Select Partners, LP
	  	$	700,000	  	$	568,841
			
	 Whitebox Intermarket Partners, LP
	  	$	500,000	  	$	406,522
			
	 Wolverine Convertible Arbitrage Fund Trading Ltd.
	  	$	3,000,000	  	$	1,500,000
			
	 Rockmore Investment Fund, Ltd.
	  	$	1,000,000	  	$	300,000

  

 17Change in Control Agreement

 Exhibit 10.3 
 ANDREA ELECTRONICS CORPORATION 
 CHANGE IN CONTROL 
 The Board of Directors (the “Board”) of Andrea Electronics Corporation (the “Company”), a New York corporation, desires to assure the Company of your
continued services for the benefit of the Company, particularly in the face of a take over attempt. 
 This Change in Control agreement
(“Agreement”) therefore sets forth those benefits which the Company will provide to you in the event your employment with the Company is terminated after a “Change in Control of the Company” (as defined in paragraph 2) under the
circumstances described below. 
  

	1)	TERM 

 If a Change in Control of the Company should occur while you
are still an employee of the Company, then this Agreement shall continue in effect from the date of such Change in Control of the Company for so long as you remain an employee of the Company, but in no event for more than three full calendar years
following a Change in Control of the Company; provided, however, that the expiration of the term of this Agreement shall not adversely affect your rights under this Agreement which have accrued prior to such expiration. If no Change in Control of
the Company occurs before your status as an employee of the Company is terminated, this Agreement shall expire on such date. 
  

	2)	CHANGE IN CONTROL 

  

	 	a)	For purposes hereof, a “change in control” shall be defined as: 

  

	 	i)	The acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”)) (a “Person”) of beneficial ownership (within the meaning of Rule 13D-3 promulgated under the Exchange Act) of 20% or more of either (A) the then outstanding shares of common stock of the Company (the “Outstanding
Company Common Stock”) or (B) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of Directors (the “Outstanding Company Voting Securities”); provided,
however, that for purposes of this subsection (I), the following acquisitions shall not constitute a Change of Control: (i) any acquisition directly from the Company, (ii) any acquisition by the Company, (iii) any acquisition by any
employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company or (iv) any acquisition by any corporation pursuant to a transaction which complies with clauses (A), (B) and
(C) of subsection (iii) below: or 

  

	 	ii)	Individuals who, as of the date hereof, constitute the Committee (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Committee, provided,
however, that any individual becoming a director subsequent to the date hereof whose election or nomination for election by the Company’s shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent
Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with
respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Committee; or 

  

	 	iii)	Consummation of a reorganization, merger, consolidation or sale or other disposition of all or substantially all of the assets of the Company (a “Business Combination”),
in each case, unless, following such Business Combination, (A) all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting
Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 60% or, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities
entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns the Company or all or
substantially all of the Company’s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Company Common Stock and
Outstanding Company Voting Securities, as the case may be, (B) no Person (excluding any employee benefit plan (or related trust) of the Company or such corporation resulting from such Business Combination) beneficially owns, directly or
indirectly, 20% or more of, respectively, the then outstanding shares of common stock of the corporation resulting from such Business Combination or the combined voting power of the then outstanding voting securities of such corporation except to
the extent that such ownership existed prior to the Business Combination and (C) at least a majority of the members of the board of directors of the corporation resulting from such Business Combination were members of the incumbent Board at the
time of the execution of the initial agreement, or of the action of the Committee, providing for such Business Combination; or 

	 	iv)	Approval by the shareholders of the Company of a complete liquidation or dissolution of the Company. 

  

	 	b)	Upon the occurrence of a Change in Control, the Company shall pay Employee, or in the event of his subsequent death, his beneficiary or beneficiaries, or his estate, as the case may
be, a sum equal to the greater of the payments due for the remaining term of the Agreement or three (3) times Employee’s average annual compensation for the five (5) preceding taxable years. Such annual compensation shall include
bonuses, pension and profit sharing plan benefits, severance payments, retirement benefits and fringe benefits paid or to be paid to the Employee during such years. Such annual compensation shall not include any commissions. At the election of the
Employee, which election is to be made within thirty (30) days of the Change in Control, such payment may be made in a lump sum or paid in equal monthly installments during the thirty-six (36) months following the Employee’s
termination. In the event that no election is made, payment to the Employee will be made on a monthly basis during the thirty-six (36) months following the Employee’s termination. 

  

	 	c)	All restrictions on the restricted stock will lapse immediately, incentive stock options and stock appreciation rights will become immediately exercisable, and Performance
Shares/Units will vest immediately, in full, in the event of a Change in Control. 

  

	 	d)	Upon the occurrence of a Change in Control, Employee will be entitled to receive benefits due him under or contributed by the Company on his behalf pursuant to any retirement,
incentive, profit sharing, bonus, performance, disability or other employee benefit plan maintained by the Company on Employee’s behalf to the extent such benefits are not otherwise paid to Employee under a separate provision of this Agreement.

  

	 	e)	Upon the occurrence of a Change in Control followed by the Employee’s termination of employment, the Company will cause to be continued life, medical, dental and disability
coverage substantially identical to the coverage maintained by the Company for Employee prior to his severance, except to the extent that such coverage may be changed in its application for all Company employees on a nondiscriminatory basis. Such
coverage and payments shall cease upon the expiration of thirty-six (36) full calendar months following the Date of Termination. 

  

	 	f)	Any and all payments to be made to the Employee under this Agreement or otherwise as a result of a Change in Control (hereinafter referred to as “Change in Control
Payments”), shall be made free and clear of, and without deduction or withholding for or on account of, any tax which may be payable under Section 4999 of the Code, now or hereafter imposed, levied, withheld or assessed (such amounts being
hereinafter referred to as the “Excise Taxes”). If, notwithstanding the foregoing provision, any Excise Taxes are withheld from any Change in Control Payments made or to be made to Employee, the amounts so payable to the Employee shall be
increased to the extent necessary to yield to the Employee (after payment of any tax which may be payable under Section 4999 of the Code) the full amount which he is entitled to receive pursuant to the terms of this Agreement or otherwise
without regard to liability for any Excise Taxes and any other Federal, State, FICA/Medicare and unemployment taxes thereon. In the event any Excise Taxes are now or hereafter imposed, levied, assessed, paid or collected with respect to the Change
of Control Payments made or to be made to the Employee, Excise Taxes and any other Federal, State and unemployment taxes thereon shall be paid by the Company or, if paid by the Employee, shall be reimbursed to the Employee by the Company upon its
receipt of satisfactory evidence of such payment having been made. 

 SIGNATURES 
 IN WITNESS WHEREOF, Andrea Electronics Corporation has caused this Agreement to be executed and its seal to be affixed hereunto by its duly authorized
officer and its directors, and Employee has signed this Agreement, on the 22nd day of November, 1999. 
  

	
	 /s/ Richard A. Maue

	Richard A. Maue
	Chief Financial Officer and Corporate Secretary
	
	 /s/ Corisa Guiffre

	Corisa Guiffre

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]